Back to Search
MICHAEL HOLTZ, M.D.
Emergency Medicine Physician
NPI: 1134461908IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
17129(NV)MD456914(PA)
Education
EASTERN VIRGINIA MEDICAL SCHOOL
Class of 2013
Research & Publications (20)
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
PMID 18273048·Leukemia·2008
8-other
Endothelial-specific ablation of serum response factor causes hemorrhaging, yolk sac vascular failure, and embryonic lethality.
PMID 18570667·BMC Dev Biol·2008
7-preclinical
The chromatin structure of the lysozyme GAS41 origin of DNA replication changes during the cell cycle.
PMID 18064355·Biol Res·2007
8-other
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
PMID 17283145·Cancer Res·2007
8-other
Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo.
PMID 17360953·J Am Soc Nephrol·2007
7-preclinical
Strain-induced disorder, phase transformations, and transformation-induced plasticity in hexagonal boron nitride under compression and shear in a rotational diamond anvil cell: in situ x-ray diffraction study and modeling.
PMID 16942156·J Chem Phys·2006
8-other
Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
PMID 15788896·Oligonucleotides·2005
8-other
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
PMID 15815728·Leukemia·2005
8-other
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
PMID 15070699·Blood·2004
8-other
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
PMID 15289338·Cancer Res·2004
4-observational
Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
PMID 15101707·Leuk Lymphoma·2004
6-review
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
PMID 12576334·Blood·2003
5-case
Glutamate receptor antagonists modulate heat shock protein response in focal brain ischemia.
PMID 12635523·Neurol Res·2003
7-preclinical
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
PMID 11986238·Blood·2002
4-observational
Selective removal of circulating immune complexes from patient plasma.
PMID 11879240·Artif Organs·2002
8-other
Rapid expression of neuronal and inducible nitric oxide synthases during post-ischemic reperfusion in rat brain.
PMID 11292448·Brain Res·2001
7-preclinical
Development of a DNA immunoadsorbent: coupling DNA on sepharose 4FF by an efficient activation method.
PMID 11119070·Artif Organs·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1800 W CHARLESTON BLVD
LAS VEGAS, NV 89102 - Phone
- (702) 383-1958
Quick Facts
- NPI
- 1134461908
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile